title: A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
authors.forename: Ellen
authors.initials: E
authors.lastname: Weisberg
authors.forename: Martin
authors.initials: M
authors.lastname: Sattler
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D015470:Leukemia, Myeloid, Acute; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000494:pharmacology; D010671:Phenylurea Compounds / Q000494:pharmacology*; D010879:Piperazines / Q000494:pharmacology*; D000077157:Sorafenib; D016159:Tumor Suppressor Protein p53; D051941:fms-Like Tyrosine Kinase 3
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D010671:Phenylurea Compounds; D010879:Piperazines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D009536:Niacinamide; C482205:nutlin 3; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3